Related Experiment Video
Updated: May 2, 2026
Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
Published on: March 17, 2020
SSX2-4 expression in early-stage non-small cell lung cancer
K B V Greve1, M Pøhl, K E Olsen
1Department of Cancer and Inflammation Research, Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Abstract:
The expression of cancer/testis antigens SSX2, SSX3, and SSX4 in non-small cell lung cancers (NSCLC) was examined, since they are considered promising targets for cancer immunotherapy due to their immunogenicity and testis-restricted normal tissue expression. We characterized three SSX antibodies and performed immunohistochemical staining of 25 different normal tissues and 143 NSCLCs. The antibodies differed in binding to two distinctive splice variants of SSX2 that exhibited different subcellular staining patterns, suggesting that the two splice variants display different functions. SSX2-4 expression was only detected in 5 of 143 early-stage NSCLCs, which is rare compared to other cancer/testis antigens (e.g. MAGE-A and GAGE). However, further studies are needed to determine whether SSX can be used as a prognostic or predictive biomarker in NSCLC.
Insights
Cancer/testis antigens SSX2-4 are rarely expressed in non-small cell lung cancers (NSCLC). Further research is needed to determine their potential as biomarkers for NSCLC immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cancer/testis antigens (CTAs) like SSX2, SSX3, and SSX4 are immunogenic and normally expressed only in testis tissue.
- CTAs are considered promising targets for cancer immunotherapy, particularly in non-small cell lung cancers (NSCLC).
Purpose of the Study:
- To investigate the expression of SSX2, SSX3, and SSX4 in NSCLC and normal tissues.
- To characterize SSX antibodies and their binding to SSX splice variants.
- To evaluate the potential of SSX antigens as biomarkers in NSCLC.
Main Methods:
- Characterization of three SSX antibodies.
- Immunohistochemical staining of 25 normal human tissues and 143 NSCLC samples.
- Analysis of SSX2 splice variants and their subcellular localization.
Main Results:
- Antibodies showed differential binding to SSX2 splice variants, indicating distinct functions.
- SSX2-4 expression was detected in only 5 out of 143 early-stage NSCLC cases, a low frequency compared to other CTAs.
- Expression patterns varied, with different subcellular staining observed for SSX2 splice variants.
Conclusions:
- SSX2-4 expression is rare in NSCLC, suggesting limited utility as a widespread immunotherapy target based on current findings.
- The differential expression and localization of SSX2 splice variants warrant further investigation into their specific roles.
- Additional studies are required to ascertain if SSX antigens can serve as prognostic or predictive biomarkers for NSCLC.
